Jaguar Health Expands Study on Canalevia-CA1 for Dogs

Jaguar Health, Inc. has announced the enrollment of four dogs in its ongoing study of Canalevia-CA1, an FDA conditionally approved drug for treating chemotherapy-induced diarrhea (CID) in dogs. Six veterinary oncology clinics have joined the study, with discussions underway for additional participation.

Canalevia-CA1, featuring crofelemer, aims to treat general diarrhea in dogs. Jaguar Health is pursuing partnerships for regulatory approval and global commercialization. The European Medicines Agency may review trial results for potential EU approval. Diarrhea is a prevalent health issue in dogs, but there's a lack of FDA-approved treatments.

Jaguar plans to identify a partner for developing and commercializing Canalevia for general diarrhea. The company emphasizes meeting the unmet medical need identified by U.S. veterinarians. Canalevia-CA1, a botanical-based prescription, is currently distributed by leading U.S. veterinary suppliers.